The finance will enable Cizzle to progress its research into a potential new method of diagnosing and treating lung cancer, based on the discovery of the role that the protein Ciz 1 appears to play in triggering DNA replication and cell growth. As cancer is associated with abnormal cell growth, the Cizzle team ultimately hope to confirm that blocking the actions of this protein will prevent tumours from occurring or slow down the growth of existing tumours.
The company is based on the research of Dr Dawn Coverley, Lister Research Fellow in the School of Biology at the University of York, and her collaborator Dr Justin Ainscough. She says: “Our research shows that Ciz 1 plays a role in initiation of DNA replication, and recent evidence suggests that this role is disrupted in lung cancer cells. We aim to target the disrupted form of Ciz1 to generate a completely new and selective way of both diagnosing and treating small cell lung cancers. Current chemotherapies restrain the growth of all cells in the body and therefore have poorly tolerated side effects, but what we are trying to do is target the lung cancer cells specifically.”
Lung cancers are the second most common form of cancer in the West but are the most common cause of cancer death. Small cell lung cancers, associated with cigarette smoking, account for 25 per cent of all lung cancers. Cizzle plans to develop a diagnostic test and therapy to combat this specific cancer, filling a significant gap in this market. It is also possible that this technology may be applicable to other cancers.
Coverley, whose work in this area was supported by the Yorkshire Forward Bioscience Yorkshire Enterprise Fellowship scheme (BYEF) will become Chief Scientific Officer. Simon Ward, an experienced bioscience entrepreneur who set up Sheffield biotech company Molecular Skincare Ltd, then oversaw its merger into AIM listed York Pharma was Coverley’s mentor during her time within the BYEF programme. Ward will provide consultancy services to the company.Dr Joe Wiley, Fund Manager of the White Rose Technology Seedcorn Fund said:
Dr Joe Wiley | alfa
Molecular doorstop could be key to new tuberculosis drugs
20.03.2018 | Rockefeller University
Modified biomaterials self-assemble on temperature cues
20.03.2018 | Duke University
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
20.03.2018 | Physics and Astronomy
20.03.2018 | Physics and Astronomy
20.03.2018 | Earth Sciences